PMC:4822111 / 25808-26770 JSONTXT

{"project":"2_test","denotations":[{"id":"27066091-21376385-56335839","span":{"begin":218,"end":220},"obj":"21376385"},{"id":"27066091-25605862-56335840","span":{"begin":372,"end":374},"obj":"25605862"},{"id":"27066091-20555089-56335841","span":{"begin":956,"end":958},"obj":"20555089"},{"id":"27066091-21947834-56335842","span":{"begin":956,"end":960},"obj":"21947834"}],"text":"Nausea and vomiting\nNausea and vomiting are among the most common gastrointestinal AEs associated with eribulin therapy. In the EMBRACE study, 35% and 18% of the patients experienced nausea and vomiting, respectively [21]. However, these AEs were usually mild, with grade 3 and 4 toxicities occurring in \u003c1% of patients. A low incidence of both AEs was seen in Study 301 [22]. Although the emetogenic potential of eribulin is common, it is considered low in comparison to that of the other antineoplastic agents such as cisplatin, doxorubicin, and cyclophosphamide [58]. Based on our clinical experience, eribulin-induced nausea and vomiting are relatively uncommon and anti-emetic prophylaxis is usually not necessary for Asian patients. If these AEs do occur, treatment guidelines for managing chemotherapy-induced nausea and vomiting can be followed, such as the guidelines of the Multinational Association of Supportive Care in Cancer, ASCO, and NCCN [5960]."}